Background: Millions of Americans are burdened by overactive bladder (OAB) syndrome
and the psychogenic and economic hardships that accompany it. Several theories attempt to …

Purpose Overactive bladder (OAB) syndrome is one of the most common diseases in
urology and affects quality of life. Although the current treatment for OAB is based on oral …

Background: Neurogenic detrusor overactivity (NDO) is treated with antimuscarinics as first-
line treatment. For patients with contraindications or unresponsive, intradetrusor injections …

Objective The contribution of genetic factors to the presence of an overactive bladder is
recognized. This study aimed to (1) assemble and synthesize available data from studies …

Background Overactive bladder (OAB) presents a high prevalence of 16–18% worldwide.
The pathophysiology of OAB is still poorly understood while effective therapy or …

Mirabegron is a drug used in overactive bladder (OAB) treatment. Genetic variation in
pharmacogenes might alter its pharmacokinetics, affecting its efficacy and safety. This …

Background Mirabegron (MIRG) is a type of β3 adrenoceptor agonist that is considered an
alternative therapy for the treatment of overactive bladder (OAB) symptoms. Cilostazol (CITZ) …

Enhanced electrical activity in detrusor smooth muscle (DSM) cells is a key factor in detrusor
overactivity which causes overactive bladder pathological disorders. Transient receptor …

Background Overactive bladder, a syndrome marked by an urgent need to urinate, is a
globally prevalent ailment. Human health and quality of life are seriously affected. Therefore …

Objective The aim of this cross-sectional study was to investigate the association of HEI-
2015 and overactive bladder (OAB) in a large population. Methods Data were retrieved from …